A Pleiotropic Role for the Orphan Nuclear Receptor Small Heterodimer Partner in Lipid Homeostasis and Metabolic Pathways by Garruti, Gabriella et al.
Hindawi Publishing Corporation
Journal of Lipids
Volume 2012, Article ID 304292, 22 pages
doi:10.1155/2012/304292
Review Article
A Pleiotropic Role for the Orphan Nuclear
ReceptorSmallHeterodimerPartner inLipidHomeostasis
andMetabolic Pathways
GabriellaGarruti,1,2 Helen H. Wang,2 Leonilde Bonfrate,3 OrnelladeBari,2,3
DavidQ.-H.Wang,2 and PieroPortincasa3
1Section of Endocrinology, Department of Emergency and Organ Transplantations, University of Bari “Aldo Moro” Medical School,
Piazza G. Cesare 11, 70124 Bari, Italy
2Division of Gastroenterology and Hepatology, Department of Internal Medicine, Edward Doisy Research Center,
Saint Louis University School of Medicine, 1100 S. Grand Boulevard, Room 205, St. Louis, MO 63104, USA
3Department of Biomedical Sciences and Human Oncology, Clinica Medica “A. Murri”, University of Bari Medical School,
Piazza G. Cesare 11, 70124 Bari, Italy
Correspondence should be addressed to Piero Portincasa, p.portincasa@semeiotica.uniba.it
Received 8 August 2011; Accepted 5 December 2011
A c a d e m i cE d i t o r :B .A .N e u s c h w a n d e r - T e t r i
Copyright © 2012 Gabriella Garruti et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Nuclear receptors (NRs) comprise one of the most abundant classes of transcriptional regulators of metabolic diseases and have
emerged as promising pharmaceutical targets. Small heterodimer partner (SHP; NR0B2) is a unique orphan NR lacking a DNA-
bindingdomainbutcontainsaputativeligand-bindingdomain.SHPisatranscriptionalregulatoraﬀectingmultiplekeybiological
functions and metabolic processes including cholesterol, bile acid, and fatty acid metabolism, as well as reproductive biology and
glucose-energy homeostasis. About half of all mammalian NRs and several transcriptional coregulators can interact with SHP.
The SHP-mediated repression of target transcription factors includes at least three mechanisms including direct interference with
the C-terminal activation function 2 (AF2) coactivator domains of NRs, recruitment of corepressors, or direct interaction with
the surface of NR/transcription factors. Future research must focus on synthetic ligands acting on SHP as a potential therapeutic
target in a series of metabolic abnormalities. Current understanding about the pleiotropic role of SHP is examined in this paper,
and principal metabolic aspects connected with SHP function will be also discussed.
1.Introduction
Nuclearreceptors(NRs)constituteauniquefamilyofligand-
modulated transcription factors. NRs mediate cellular re-
sponsetosmalllipophilicendogenousandexogenousligands
[1, 2] and are responsible for sensing a number of hormones,
including steroid and thyroid hormones, and act as positive
and negative regulators of the expression of speciﬁc genes
[3–5]. Therefore, NRs play a central role in many aspects of
mammalian development, as well as lipid homeostasis, phys-
iology, and metabolism. NRs make up one of the most abun-
dant classes of transcriptional regulators in the body and
have emerged as promising pharmaceutical targets.
Classically, NRs consist of several functional domains,
that is, a variable N-terminal ligand-independent transacti-
vationdomain(whichoftenexhibitsaconstitutivetranscrip-
tion activation function (AF-1)), a highly conserved DNA-
binding domain (DBD) that contains two zinc ﬁngers, a
hinge domain (a variable linker region), and a multifunc-
tional C-terminal domain. Furthermore, the C-terminal do-
main includes the ligand binding (LBD), the dimerization
interface, and the ligand-dependent transactivation domain
AF-2 [1, 6].
Small heterodimer partner (SHP; NR0B2 for nuclear
receptor subfamily 0, group B, member 2; MIM number
604630, 601665) is a member of the mammalian NR2 Journal of Lipids
superfamily, due to the presence of a putative ligand-binding
domain (LBD) [7]. SHP functions as a corepressor through
heterodimeric interaction with a wide array ofnuclear recep-
tors and repressing their transcriptional activity. SHP
achieves its goal via several members of the NR superfamily
that are able to regulate SHP expression. However, SHP is
also a unique and atypical NR because it lacks the classical
DNA-binding domain (DBD), generally present in other
NRs [8]. The NR0B family of NRs consists of 2 orphan
receptors: SHP and DAX-1 (dosage-sensitive sex reversal
adrenal hypoplasia congenita (AHC) critical region on the
X chromosome, gene 1). DAX1 is a gene whose mutation
causes the X-linked adrenal hypoplasia congenita [9]a n d
is the only family member that lacks a conventional DBD.
DAX-1 (NR0B1) is therefore seen as the closest relative
of SHP in the NR superfamily [10–12]. Both SHP and
DAX-1 appear to be speciﬁc to vertebrates. In this respect,
no homologous genes have been found in Drosophila
melanogaster or Caenorhabditis elegans [12]. Whereas SHP
is diﬀerent from other conventional NRs both structurally
and functionally, it acts as a ligand-regulated receptor
in metabolic pathways [13]. SHP belongs to the orphan
subfamily since there is no known ligand for this recep-
tor, except for some retinoid-related molecules [14]. SHP
inhibits transcriptional activation by working on several
other nuclear receptors, that is, directly modulating the
activities of conventional nuclear receptors by acting as
an inducible and tissue-speciﬁc corepressor [12, 15]. The
discovery of SHP dates back to 1996 [10]; since then, this
orphan NR has been identiﬁed as a key transcriptional reg-
ulator of signaling pathways [8, 16] involving fundamental
biological functions and metabolic processes. Such processes
include cholesterol, bile acid and fatty acid metabolism, glu-
cose and energy homeostasis, and reproductive biology [17].
Experiments performed by ﬂuorescence in situ hybridization
(FISH) analysis of the human metaphase chromosome have
shown that SHP is found at a single locus on chromosome
1 at position 1p36.1 and consists of two exons and a single
intron spanning approximately 1.8 kb with 257 amino acids
in humans [18]. In mice and rats, SHP resides on chromo-
somes 4 and 5, respectively, both consisting of 260 amino
acids. SHP expression is predominantly observed in the liver
[10, 18], but it is also detected at lower levels in other
tissues, including the pancreas, spleen, small intestine, colon,
gallbladder, kidney, adrenal gland, ovary, lung, brainstem,
cerebellum, heart, and thymus (Table 1)[ 19–21].
The genomic structure and human SHP domain struc-
ture are depicted in Figure 1 [15]. SHP is indeed able to
repress the transcriptional activities of its target NRs and
transcriptional regulators through two functional Leu-Xaa-
Xaa-Leu-Leu- (LXXLL-) like motifs [22–24]. Such motifs
appear to be essential for the interaction with the (activation
function2)AF-2domains ofseveralsetsofNRs[22,23].The
human SHP is enriched by another 12 amino acids [25–36],
and this region between helix 6 and 7 is also involved in the
repression of the transactivation of NRs [37].
About half of all mammalian NRs and several transcrip-
tional coregulators can interact with SHP [12]. Since SHP
lacks DNA-binding domain, it exerts the inhibitory eﬀects
Table 1: Small heterodimer partner (SHP) expression [10, 18–21].
LIVER (greater)∗
Spleen
∗
Pancreas
∗
Central nervous system (brainstem and cerebellum)
Adrenal gland
∗
Intestine (duodenum
∗, jejunum
∗,i l e u m
∗, and colon)
Gallbladder, stomach
∗, kidney
∗, ovary, lung, prostate, testis,
uterus, heart
∗, thymus, and epididymis
All organs in the mouse. Astericks indicate SHP expression in humans [18,
133].
through protein-protein interaction [10]. SHP expression
seems to follow a circadian rhythm in the liver, involving the
CLOCK-BMAL1 pathway and suggesting that some of the
regulatory functions of SHP and deriving functions must be
temporal [19, 20, 38].
Gene expression of SHP is regulated by several factors
including NRs, transcription factors, and a number of addi-
tional conditions and substances, as extensively reported in
Table 2. Also, the central role of SHP is clear since this NR is
able to act as a coregulator for wide range of targets, namely,
NRs/transcription factors/transcriptional coregulators and
few diﬀerent molecules, as depicted in Table 3. In general,
SHP acts as a repressor of the transcriptional activity of the
speciﬁc interacting partner (via LBD of the partner and NR
boxes of SHP) [12, 39–43]. However, it is also demonstrated
that SHP is able to upregulate gene transcription, as in the
case of PPARα and PPARγ [44–46]a n dN F - κB[ 44].
Both N-terminal NR interaction domain and C-terminal
domain of SHP are important for repression [47, 48]. Over-
all, the SHP-mediated repression of target transcription fac-
torsoccursbyatleastthreedistincttranscriptionalrepression
mechanisms (Figure 2).
A ﬁrst mechanism involves direct interference with the
AF-2 coactivator domain of NRs (competition for coacti-
vator binding, leading to the repression of NR-mediated
transcriptional activity). This is the case for the inhibition
of estrogen receptor α (ERα)a n de s t r o g e nr e c e p t o rβ (ERβ)
[49].
A second mechanism for the SHP-mediated repression
involves the recruitment of corepressors including direct
interactions among mammalian homolog of the Saccharo-
myces cerevisiae transcriptional corepressor Sin3p (mSin3A),
human Brahma (Brm), SWItch/Sucrose NonFermentable
(SWI/SNF) complexes leading to the repression of choles-
terol 7α-hydroxylase (CYP7A1) [50]).
A third mechanism of inhibition of SHP involves the
direct interaction with the surface of NR or transcription
factor, resulting in the blockade of DNA binding and the
consequent inhibition of its transcriptional activity. This is
the case for RAR-RXR heterodimers [10], PXR-RXR binding
to DNA by SHP [1], interaction with hepatocyte nuclear
factor(HNF4),orJunfamilyoftheactivatorprotein1(AP-1)
transcription factor complex (JunD) [51, 52].Journal of Lipids 3
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Figure 1: Top: the genomic structure of human SHP. Rectangles represent the two exons with a single intron spanning approximately 1.8
kilobases and located on a single locus on chromosome 1p36.1 [18]. The region 5  includes ≈600 nucleotides from the transcription start
site and is characterized by promoter activity. Bottom: typical nuclear receptor is compared with the domain structure of human SHP.
The canonical structure of NR includes the N-terminal activation function 1 (AF1) domain, DNA-binding domain (DBD), ligand-binding
domain (LBD), and C-terminal activation function 2 (AF2) domain. SHP lacks the DBD. Two functional LXXLL-related motifs (also named
as NR boxes) are typical of the human SHP structural domains. Such motifs are located in the putative N-terminal helix 1 of the LBD and
in the C-terminal region of the helix 5. While active NRs exhibit glutamic acid in AF-2, the SHP AF-2 domain is replaced with aspartic acid.
Adapted from Chanda et al. [15] and Shulman and Mangelsdorf [130].
All three mechanisms might occur sequentially or alter-
natively according to type of cells and promoters [12].
Clearly, information on factors that increase or decrease
SHP expression and that are regulated by SHP is essential
for understanding the regulatory eﬀects of this orphan NR.
Few years of research have not been enough to identify a true
ligand. Interestingly, it is suggested that targeting posttrans-
lationalmodiﬁcationsofSHPmaybeaneﬀectivetherapeutic
strategy. Selected groups of genes could be controlled to cure
a vast range of metabolic and SHP-related diseases [53].
Overall, the huge amount of information on SHP function
is currently available, making this NR essential in a number
of functions involving cholesterol and bile acid metabolism,
lipogenesis, glucose metabolism, steroid hormone biosyn-
thesis, xenobiotic homeostasis/metabolism, and cell cycle.
In particular, the ability of SHP in interacting with dif-
ferent metabolic signaling pathways including bile acids and
lipid homeostasis, fat mass, adipocytes, and obesity will be
reviewed here.
2.Bile Acids andLipid Homeostasis
The wide ability of SHP to target multiple genes in diverse
signaling pathways points to the key role of SHP in various
biological processes, including the metabolism of bile salts,
glucose, and fatty acids. Both unique structure and func-
tional properties account for the complexity of SHP signal-
ing. Studies suggest that loss of SHP might positively aﬀect
cholesterol and bile acid homeostasis in pathophysiologically
relevant conditions [54]. Bile acids (BAs) are amphipatic
cholesterol metabolites which are synthesized in the liver,
secreted into bile, stored in the gallbladder, and secreted
postprandially into the duodenum. BAs are synthesized from
cholesterol, and this pathway provides the elimination of
excess cholesterol in the body [55]. Moreover, BAs should be
seen as physiological detergents which, in the small intestine,
are essential for the absorption, transport, and distribution
oflipophilicmolecules,includingdietarylipids,steroids,and
lipid-soluble vitamins. In the intestine, BAs undergo exten-
sive metabolism by the intestinal microﬂora. A high eﬃcient
system is the enterohepatic circulation of BAs [55, 56], where
more than 90–95% of BAs are returned to the liver from the
terminal ileum via the portal vein. Thus, the concentration
of BAs in serum, liver, and intestine is tightly regulated to
prevent damage to enterohepatic tissues due to their strong
detergent moiety [57–59]. The major rate-limiting step in
biosynthetic pathway of BAs in humans is initiated by
cholesterol 7α-hydroxylase (CYP7A1), the microsomal P450
liver enzyme, to produce two primary BAs, cholic acid, and
chenodeoxycholic acid, essential in the overall balance of
cholesterol homeostasis. Sterol 12α hydroxylase (CYP8B1)
catalyzesthesynthesisofcholicacid,astepwhichdetermines
the cholic acid to CDCA ratio in the bile [60]. Secondary
bile acids (deoxycholic acid and lithocholic acid) and tertiary
bile acids (ursodeoxycholic acid) in humans are produced
following intestinal dehydroxylation of primary bile acids by
intestinal bacteria [58, 61].
Regulation of BA biosynthesis is highly coordinated and
is mediated by key NRs including the orphan receptor,
liver receptor homologue-1 (LRH1; NR5A2), the hepatocyte
nuclear factor 4α (HNF4α), SHP, and the bile acid receptor
farnesoid X receptor (FXR; NR1H4). Thus, the activation
of FXR initiates a feedback regulatory loop via induction
of SHP, which suppresses LRH-1- and HNF4α-dependent4 Journal of Lipids
Table 2: Regulators of the Shp gene promoter [12, 39–43].
(1) Nuclear receptors
Protein Model(s)/putative function
ERα Uterus, pituitary, kidney, and adrenal gland, HepG2 cell lines/biological eﬀects of estrogens, LDL/HDL
metabolism [134].
ERRα, β, γ
S H Pp r o m o t e ri sa c t i v a t e db yt h eE R R γ, while SHP inhibits ERRγ transactivation (autoregulatory loop).
SHP and ERRγ coexpressed in several tissues (e.g., pancreas, kidney, and heart). Role in some forms of
moderate obesity? SHP also physically interacts with ERR α and β isoforms (yeast two-hybrid and
biochemical assays) [133].
FXR Downregulation of CYP7A1-mediated bile acid biosynthesis by the FXR/SHP/LRH-1 cascade in the liver
[64].
LXRα Direct regulation of SHP and repression of CYP7A1-mediated bile acid biosynthesis (in humans not in
rodents). Eﬀect on cholesterol homeostasis [135].
LRH-1
Liver/formation of heterodimeric SHP/LRH-1 complex > inactivation of LRH-1 > SHP repression
(autoregulatory negative feedback) [64, 65, 136]. Also involved in the CLOCK-BMAL1 circadian
activation of SHP [38].
PPARγ
Liver/PPARγ decreases gluconeogenic gene expression by the PPARγ/RXRα heterodimer binding to the
PPRE in the human SHP promoter. A mechanism explaining the SHP-mediated acute antigluconeogenic
eﬀects of PPARγ [137].
SF-1 At least ﬁve binding sites for SF-1 detected in the promoter region of SHP. Rat testis and adrenal glands,
human fetal adrenal gland [136].
(2) Transcription factors
Protein Model(s)/putative function
CLOCK-BMAL1
Liver/SHP displays a circadian expression pattern involving CLOCK-BMAL1 (core circadian clock
component). Regulation of SHP promoter together with LRH-1 and SHP. Relevance for circadian liver
function? [38].
E2A proteins (E47, E12,
E2/5)
HepG2, HeLa, and CV-1 cells/bHLH transcription factors, the E2A proteins activate human (not mouse)
hSHP promoter. E47 and SF-1 stimulate cooperatively SHP promoter. The Id protein inhibits E47 binding
to hSHP promoter. A role for tissue-speciﬁc gene regulation, B-cell diﬀerentiation, tumor suppression?
[138].
HNF-1α Liver/modulation of bile acid and liver cholesterol synthesis via the FXR/SHP/LRH-1 complex and eﬀect
on CYP7A1 [69].
HNF4α
Pancreatic β-cells/decreased expression of SHP may be indirectly mediated by a downregulation of
HNF4α. SHP can repress its own transcriptional activation by inhibiting HNF4 α function (feedback
autoregulatory loop) and, indirectly (via HNF4 α), HNF1α function. Relevance for pancreatic islet
diﬀerentiation, insulin secretion, synthesis [116].
JNK/c-Jun/AP-1
Primary rat hepatocytes/bile acid downregulation of CYP7A1-dependent bile acid biosynthesis via the
JNK/cJun/AP1 pathway. SHP promoter is a direct target of activated c-Jun binding to AP-1 element [139].
Also, in HL-60 leukemia cells, c-Jun increases the transcriptional activation of the SHP promoter to
activate the expression of Shp genes associated with the cascade regulation of monocytic diﬀerentiation
[140].
SMILE
HEK-293T, HepG2, MCF-7, T47D, MDA-MB-435, HeLa, PC-3, C2C12, NIH 3T3, K28, Y-1, and TM4 cell
lines/SMILE isoforms (SMILE-L and SMILE-S) regulate the SHP-driven inhibition of ERs transactivation
in a cell-type-speciﬁc manner [25, 26, 39].
SREBP-1 Liver/eﬀect on human (not mouse) SHP promoter. Cholesterol and bile acid homeostasis, fatty acid
synthesis [27].
USF-1
HepG2, H4IIE, and AML12 cells/HGF activates AMPK signaling pathway in hepatocytes, E-box-binding
transcription factor USF-1, and binding to the Shp gene promoter. SHP induction of gene expression
leads to inhibition of hepatic gluconeogenesis due to SHP-repressed transcription factor HNF4α [28].
(3) Transcriptional coregulators
Protein Model(s)/putative function
RNF31
NCI-H295R (H295R) adrenocortical carcinoma cell line, COS-7 and HeLa cells/RNF31 interacts with
SHP, stabilizes DAX-1, and is required for DAX-1-mediated repression of transcription. Relevant as
coregulator of steroidogenic pathways [43].
SRC-1
Murine macrophage cell line RAW 264.7, HeLa, and CV-1 cells/SHP interacts negatively with SRC-1 (a
transcription coactivator of nuclear receptors and other transcription factors including NF-κB). See also
oxLDL in this table [44].Journal of Lipids 5
Table 2: Continued.
(4) Other SHP inducers
Factor Model(s)/putative function
Bile acids (ﬁnal
intermediates)
Experiments in HepG2 cells/treatment with chenodeoxycholic acid and late intermediates in the classic
pathway of bile acid synthesis: 26-OH-THC (5β-cholestane-3α,7α,12α,26-tetrol), THCA
(3α,7α,12α-trihydroxy-5 β-cholestanoic acid), 26-OHDHC (5β-cholestane-3α,7α,26-triol), DHCA
(3α,7α-dihydroxy-5β-cholestanoic acid) resulted in 2.4-6.5-fold increase in SHP mRNA expression [132].
Conﬁrmed by Ourlin et al. with the two FXR ligands chenodeoxycholic acid and cholic acid [1].
Guggulsterone (plant
sterol)
Active extract from Commiphora Mukul. FXR antagonist. In Fisher rats, guggulsterone increased
transcription of bile salt export pump (BSEP) mRNA and SHP expression [29].
GW4064 (ligand)
Synthetic FXR-selective agonist [29]. In primary cultured human hepatocytes, GW4064 treatment was
associated with a marked induction of SHP (≈70-fold) and complete suppression of CYP7A1[ 64, 65]. In
HepG2 cells, GW4064 (1uM) induced a 3.9-fold increase in SHP mRNA expression. Conﬁrmed by [30].
Interleukins (various)
IL-1Ra (−/−) mice/high cytokine levels in IL-1Ra (−/−) mice reduce mRNA expression of CYP7A1 with
concurrent upregulation of SHP mRNA expression [31]. SHP signiﬁcantly expressed in
IFN-γ/CH11-resistant HepG2 cells [32].
PGC-1α (gene expression
inducer)
COS-7 cell lines/PGC-1α mediates the ligand-dependent activation of FXR and transcription of Shp gene.
Relevance in mitochondrial oxidative metabolism in brown fat, skeletal muscle, and liver gluconeogenesis
[33].
PMRT1 (group of protein
arginine
methyltransferases)
Hepatic cell lines/PRMT1 functions as FXR coactivator and has a role in chromatin remodeling. PRMT1
induces BSEP and SHP and downregulation of NTCP and CYP7A1 (targets of SHP) [30].
Procyanidins
(polyphenols)
Grape seed procyanidin extract is given orally in male Wistar rats. Increase of liver mRNA levels of small
heterodimer partner (SHP) (2.4-fold), cholesterol 7α-hydroxylase (CYP7A1), and cholesterol biosynthetic
enzymes with improved lipidogenic proﬁle and atherosclerotic risk [34].
(5) Factors/conditions associated with SHP repression
β Klotho (type I
membrane protein)
In βKlotho (−/−) mice: enhanced bile acid synthesis with attenuation of bile acid-mediated induction of
Shp. βKlotho involved in CYP7A1 selective regulation [35].
IL-1β (interleukin) SHP downregulation [36].
oxLDL (oxidized low
density lipoprotein)
Murine macrophage cell line RAW 264.7, HeLa, and CV-1 cells/oxLDL decreased SHP expression. SHP
transcription coactivator of NF-κB which became progressively inert in oxLDL-treated RAW 264.7 cells
(see also Table 3). Relevance for diﬀerentiation mechanism of resting macrophage cells into foam cells and
resulting atherogenesis [44].
AP-1:adaptorprotein-1;bHLH:basichelix-loop-helix;DAX1:dosage-sensitivesexreversaladrenalhypoplasiacongenitacriticalregionontheXchromosome,
gene 1; E2A: E2A2 gene products belonging to the basic helix-loop-helix (bHLH) family of transcriptor factors; ERα:e s t r o g e nr e c e p t o r α;E R R γ:e s t r o g e n
receptor-related receptor-γ; FXR: farnesoid X receptor; HGF: Hepatocyte growth factor; HNF-1α: hepatocyte nuclear factor-1α;H N F 4 α: hepatocyte nuclear
factor-4α; Id: inhibitor of diﬀerentiation; IL-1Ra (−/−): interleukin-1 receptor antagonist; JNK: Jun N-terminal kinase; LRH-1: liver receptor homologue-
1; LXRα:l i v e rXr e c e p t o r α;N F κB: nuclear factor-κB; NR: nuclear receptor; NTCP: Na+-taurocholate cotransport peptide; oxLDL: oxidized low-density
lipoprotein; PGC-1: PPARγ (peroxisome-proliferator-activated receptor γ)c o a c t i v a t o r - 1 α; PMRT1: protein arginine methyltransferase type 1; PPRE: PPAR
response element; RNF31: member of the ring-between-ring (RBR) family of E3 ubiquitin ligases; RXR α: retinoid X receptor; SF-1: steroidogenic factor-1;
SHP: small (short) heterodimer partner; hSHP: human small (short) heterodimer partner; SMILE: SHP-interacting leucine zipper protein; SRC-1: steroid
receptor coactivator-1; SREBP-1: sterol regulatory element binding protein-1; USF-1: upstream stimulatory factor-1.
expression of the two major pathway enzymes cholesterol
7hydroxylase(CYP7A1)andsterol12hydroxylase(CYP8B1).
The BA feedback regulation primarily occurs since BAs
actastranscriptionalregulatorsfortheexpressionofthegene
encoding CYP7A1. Both cholic acid and chenodeoxycholic
acid function as endogenous ligands for the nuclear bile acid
receptor FXR [62]. FXR expression is high in the intestine
and liver, the two sites where BAs reach high concentrations
to activate FXR. The transcription by FXR includes heterod-
imerization with retinoid X receptors (RXRs) in the cyto-
plasm, translocation into the nucleus, and binding to DNA
response elements in the regulatory regions of target genes
[63]. When the bind of BAs to FXR, SHP transcription is
increased [60, 64, 65], this alteration leads to the inhibition
of LRH-1 activity or HNF4α on the BA response elements
(BAREs) of CYP7A1 and CYP8B1 promoters [64, 65]. In this
scenario,BAsynthesisisdownregulatedbyaprecisefeedback
regulatory mechanism, which represents the major pathway
under normal physiological conditions [64–66]( Figure 3).
LRH1 is also a well-known activator of Shp gene transcrip-
tion [64, 65], and this step leads to an autoregulatory loop of
gene expression by SHP [42]. This step also includes the G
protein pathway suppressor 2 (GPS2) interacting with FXR,
LRH-1, and HNF4α to regulate CYP7A1 and CYP8B1 ex-
pression in human hepatocytes [67]( Table 3). A critical role
inmaintainingcholesterolhomeostasisforCYP7A1hasbeen
r e c e n t l ya d v o c a t e di nam o d e lo fi nC y p 7 a 1 - t gm i c e[ 68].
Thehepatocytenuclearfactor-1α(HNF1α),whichhaplo-
insuﬃciencycausestheMaturity-onsetdiabetes oftheyoung
type 3 (MODY3), also appears to modulate SHP expression6 Journal of Lipids
Table 3: SHP targets [12, 39–43].
(1) Nuclear receptors
Protein Model(s)/putative function
AR
The AR/SHP interaction leads to >95% inhibition of AR via the LXXLL motifs. Mechanisms involve
inhibition of AR ligand-binding domain and AR N-terminal domain-dependent transactivation and
competing with AR coactivators [23].
CAR, RAR, TR
HepG2 and JEG-3 cells/early evidence that SHP interacts with several receptor superfamily members and
inhibits transactivation. CAR is an NR-inducing CYP2 and CYP3 genes involved in the metabolism of
xenobiotics [10, 24].
DAX-1
Human embryonic kidney 293 cells/beside individual homodimerization of DAX1 and SHP, this is the ﬁrst
evidence of DAX1-SHP heterodimerization in the nucleus of mammalian cells. Involvement of the LXXLL
motifs and AF-2 domain of DAX1 in this interaction. Distinct functions for SHP (diﬀerent from
transcriptional repressor) are anticipated [141, 142].
ER
293 human embryo kidney cells, Cos7 kidney cells/direct inhibitory binding of SHP to ERs via
LXXLL-related motifs to the AF-2 domain [21]. RL95-2 human endometrial carcinoma cells/SHP inhibits
the agonist activity of 4-hydroxytamoxifen displaying a potent inhibitory eﬀect for ERα> ERβ. Direct
interaction of SHP with ER and inhibition of ER transcriptional activity [143]. Prevention of
tamoxifen-induced estrogen agonistic eﬀects and neoplastic changes in the endometrium in women with
breast cancer taking tamoxifen?
ERRγ
HeLa (human cervical carcinoma), CV-1 (green monkey kidney), and HEK 293 (human embryonic kidney)
cell lines/SHP inhibits ERRγ transactivation by physical interaction with the 3 members of the ERR
subfamily. Interaction is dependent on N-terminal receptor interaction domain of SHP and AF-2 surface of
ERRγ. Part of the autoregulatory mechanism of gene expression going through ERRγ/SHP/ERRγ.A
potential role in some forms of moderate human obesity during SHP mutations [133].
GR
293 human embryo kidney cells and COS-7 monkey kidney/SHP inhibits the transcriptional activity of GR
via the LXXLL motif. Physiological role of SHP in glucocorticoid signaling and gluconeogenesis [22]. See
also HNF4 [90]a n dF o x o 1[ 115].
HNF4
Human ANG transgenic mice and HepG2 cells treated with bile acids/evidence that bile acids negatively
regulate the human ANG gene through the FXR/SHP-mediated process (inhibition of the binding of HNF4
to the ANG promoter) [90]. Mechanisms: SHP binds the AF-2 region and the N-terminal region of HNF4
and inhibits the binding of HNF4 to DNA. Also, modulation of HNF4 activity by SHP has important
metabolic eﬀects and interacts with the pathway of gluconeogenesis [47](see text and Foxo1) [115].
LRH-1
HepG2 cells/SHP interacts directly with the orphan receptor LRH-1 (AF-2 surface) and competes with other
coactivators, leading to repression of LRH-1 transcriptional activity [48]. Demonstration that repression of
CYP7A1 and bile acid synthesis requires coordinate interaction/transcription of FXR/LRH-1/SHP
autoregulatory cascade, essential for maintenance of bile acid-induced negative feedback, and therefore
hepatic cholesterol metabolism [65]( s e ea l s oFigure 2).
LXRα
In vitro experiments and in vivo human colon Caco-2 cells/SHP directly inhibits the transcriptional activity
of LXRα via the AF-2 domain. Relevance for direct downregulation of speciﬁc LXR target genes (controlling
CYP7A1, ABCA1, ABCG1, ABCG5, ABCG8, CETP, ApoE, SREBP-1c) and therefore cholesterol-bile acid
homeostasis [144].
Nur77 (NGFI-B)
HepG2 cells/Nur77 plays a key role in apoptosis of many cell types and cancer cells. Evidence that SHP
functions to repress the transcriptional function of Nur77 (binding coactivator CBP, see elsewhere in this
table). SHP plays a protective role in the Nur77-mediated apoptosis in liver. Mutations in SHP: a role also for
aﬀect initiation and progression of inﬂammatory liver diseases such as alcoholic hepatitis and hepatic viral
infections? [32].
PPARα
In vitro binding assays and in vivo experiments/the promoter regions of the genes encoding the ﬁrst two
enzymes of the peroxisomal beta-oxidation pathway (AOx, HD), contain transcriptional regulatory
sequences (PPRE) bound by the PPARα/RXRα heterodimeric complex. SHP-inhibited transcription by
PPARα/RXRα heterodimers from the AOx-PPRE. SHP potentiated transcription by PPARα/RXRα
heterodimers from the HD-PPRE (evidence of SHP-dependent upregulation PPARα-mediated gene
transcription) [46].
PPARγ
In vitro experiments, COS-7 cells/Shp gene expressed also in adipose tissue. SHP induces PPAR activation via
C terminus (direct binding to the DBD/hinge region of PPARγ) and inhibition of the repressor activity of
NCoR. SHP may act as an endogenous enhancer of PPARγ by competing with NCoR [45]. Mutant SHP
proteins display less enhancing activity for PPARy compared with wild-type SHP, and a human model
leading to mild obesity and insulin resistance has been described in Japanese during naturally occurring
mutations [111]( s e ea l s ot e x ta n dTable 3).Journal of Lipids 7
Table 3: Continued.
PXR
In vitro experiments, human hepatocytes, mouse model on cholic acid-supplemented diet/SHP act as potent
repressor of PXR transactivation. Upon sensing xenobiotics and bile acid precursors, PXR controls CYP3A
gene induction and inhibits CYP7α, acting on both bile acid synthesis and catabolism. PXR function might
be also inhibited in the presence of cholic acid, chenodeoxycholic acid-dependent SHP upregulation [1].
RXR HepG2 cells/demonstration that SHP acts as a transcriptional repressor for RXR. Full inhibition by SHP
requires its direct repressor activity [47].
SHP
Human embryonic kidney 293 cells/LXXLL motifs and AF-2 domain are involved in SHP homodimerization
in the nucleus (similarly to DAX1-SHP heterodimerization). NR0B family members use similar mechanisms
for homodimerization as well as heterodimerization. Distinct functions for SHP (diﬀerent from
transcriptional repressor) are anticipated [141, 142].
(2) Transcription factors
Protein Model(s)/putative function
ARNT
RL95-2 human endometrial carcinoma cells/TCDD binds to AHR (a member of bHLH-PAS family of
transcription factors). Studies on physical and functional interaction of SHP with the ligand AHR/ARNT
heterodimer showed that SHP inhibits the transcriptional activity of ARNT (not AHR) in vitro.C o n s e q u e n t
inhibition of binding of AHR/ARNT to XREs. [41]. Relevance for expression of several genes involved in
drug and hormone metabolism [145].
BETA2/NeuroD
293T, COS-7, CV-1 cells/BETA2/NeuroD is a member of tissue-speciﬁc class B bHLH proteins and cats as a
positive regulator of insulin gene expression [146] and neuronal diﬀerentiation [147]. SHP physically
interacts and inhibits helix-loop-helix transcription factor BETA2/NeuroD transactivation of an E-box
reporter in mouse pancreas islets. The inhibitory eﬀect of SHP requires its C-terminal repression domain,
interference with coactivator p300 for binding to BETA2/NeuroD, and direct transcriptional repression
function. Relevance for development of the nervous system and the maintenance and formation of
pancreatic and enteroendocrine cells [148].
C/EBPα
HepG2 hepatoma cells/SHP interacts directly with C/EBPα and represses C/EBPα-driven PEPCK gene
transcription. Overall, a role for SHP in regulation of hepatic gluconeogenes is driven by C/EBPα activation
in the liver [149].
Foxo1
C57BL/6J mice and HepG2 and HEK293T cells/treatment with chenodeoxycholic acid was associated with
FXR-dependent SHP induction, downregulation of gluconeogenic gene expression (G6Pase, PEPCK, FBP1),
interaction of the forkhead transcription factor Foxo1 with SHP, and repression of Foxo1-mediated G6Pase
transcription (competition with CBP). A similar mechanism is postulated for SHP-driven HNF-4 repression
of PEPCK, FBP1 transcription. A mechanism by which bile acids metabolism is linked to gluconeogenic gene
expression via an SHP-dependent regulatory pathway [115].
HNF3 (Foxa)
HepG2, 293T, NIH3T3, and HeLa cells, primary hepatocytes/SHP physically interacts and inhibits the
transcriptional activity of the forkhead transcription factor HNF3 (isoforms α, β, γ). Relevance for
SHP-driven regulation of gluconeogenic genes encoding G6Pase, PEPCK, and bile acid synthesis (CYP7A1),
via inhibition of DNA-binding of HNF3 [51].
Jun D
Two rat models of liver ﬁbrosis and Hepatic Stellate cells (HSC)/promoting the ligand-induced FXR-SHP
cascade (by the FXR ligand 6-EDCA, in rat models) and overexpressing SHP in HSC prevented ﬁbrogenic
changes in the liver. SHP binds JunD and inhibits DNA binding of adaptor protein (AP)-1 induced by
thrombin. FXR ligands as therapeutic agents to treat liver ﬁbrosis? [52].
NF-κB
Murine macrophage cell line RAW 264.7/SHP acts as a positive transcription coactivator of NF-κBa n d
essential for NF-κB transactivation by palmitoyl lysophosphatidylcholine (one of the oxLDL constituents).
Relevance for diﬀerentiation mechanism of resting macrophage cells into foam cells and resulting
atherogenesis (see also [44]).
Smad
HepG2, CV-1, and HeLa cells/SHP represses Smad3-induced transcription by competing for the coactivator
p300. SHP therefore represses TGF-β-induced gene expression. Relevance for TGF-β-dependent regulation
of cell growth, apoptosis, carcinogenesis, and regeneration following liver injury [40]. SHP-Smad3
interaction similar to SHP-BETA2/NeuroD [148].
TRAF6, p65
Macrophages/a novel function of SHP in innate immunity involving Toll-like receptors (TLRs). SHP
negatively regulates TLR signaling to NF-κB. Likely, SHP negatively regulates immune responses initiated by
various pathogen-recognition receptors by forming a complex with TRAF6 and eﬀect on TRAF6
ubiquitination. In the cytosol of LPS-stimulated cells. SHP also acts as speciﬁc transrepressor of the
transcription factor p65 (part of the p50/p65 heterodimer found in NF-κB). An additional role for SHP in
sepsis and inﬂammatory disease? [128, 129].8 Journal of Lipids
Table 3: Continued.
(3) Transcriptional coregulators
Protein Model(s)/putative function
Brm, BAF155, BAF47,
mSin3A, Swi/Snf
HepG2 cells/The CYP7A1 gene was used as a model system. SHP has direct interaction with corepressors at
the level of native chromatin. SHP directly interacted and mediated the recruitment of mSin3A-Swi/Snf-Brm
chromatin remodelling complex to the CYP7A1 promoter (TATA and BARE II region of the promoter). Also,
the mSinA3/HDAC1 corepressor complex is inhibiting transcription by histone deacetylation. SHP also
interacted with known proteins belonging to the Swi/Snf complex (BAF155, BAF47). This mechanism
explains the complex and subtle SHP-driven inhibition of hepatic bile acid synthesis [50].
CBP HepG2 cells, CV-1 cells/SHP binds coactivator CBP and competes with Nur77. The mechanism explains the
repression of the transcriptional function of Nur77, which is fundamental in apoptosis in the liver [32].
EID-1
Cos-7 cells/SHP speciﬁcally interacts with EID-1 providing inhibitory mechanisms. EID-1 (a non-HDAC
cofactor) acts as inhibitor of the coregulator complex EID1–p300–CBP. Results clarify essential repression
mechanisms of SHP involving coinhibitory factors (upstream targets) distinct from NRs corepressor
[12, 150].
G9a, HDAC-1
Caco-2, HepG2, HeLa, Cos-1 cells/SHP localized exclusively in nuclease-sensitive euchromatin regions. SHP
can functionally interact with HDAC-1 (HDAC of class I) and the euchromatic histone 3 methylase G9a, and
the unmodiﬁed K9-methylated histone 3 [151]. Additional data on mechanisms involved SHP-driven
repressive activity, involving also target genes regulated by G9a and SHP-mediated inhibition of hepatic bile
acid synthesis via coordinated chromatin modiﬁcation at target genes [152].
GPS2
Cos-7, HepG2, Huh7 cells/SHP negatively interacts with GPS2 (a stoichiometric subunit of the NR
corepressor, N-Cor) complex, involved in bile acid synthesis and diﬀerential coregulation of CYP7A1 and
CYP8B1 expression [67].
SIRT1
HepG2, HEK293T (293T), and HeLa cells/SIRT1 is a HDAC of class III. SHP recruits SIRT1 (activating
deacetylase activity of SIRT1) to repress LRH1 transcriptional activity as well as inhibition LRH1 target gene
promoter activity and mRNA levels. A novel mechanism is described for SHP repressive action and control
of bile acid homeostasis. SIRT1 in working concertedly with NRs and aﬀecting chromatin remodeling in
target gene promoters [42].
SMRT/NcoR
Hepatoma cell lines/studies on the role of SHP in CAR-mediated transactivation of the CYP2B gene. SHP
might interact with subunits of functionally distinct coregulator complexes, including
HDAC3-N-CoR-SMRT [24, 120].
(4) Others
Factor Model(s)/putative function
miRNA-206
SHP −/− mice/SHP as an important transcriptional activator of miRNA-206 gene expression via a cascade
dual inhibitory mechanism involving AP1 but also YY1 and ERRγ. Relevance for multiple steps involving
cellular development, proliferation, and diﬀerentiation [153].
RNA Pol II
Caco-2 cells/within the pathway of SHP-LXR interaction, it is shown that SHP can interact in vitro with RNA
polymerase II but not with TFIID and TFIIE transcription initiation factor II D (TFIID), general
transcription factor II E (TFIIE) (components of the basal transcription machinery). A further mechanism
by which SHP could inhibit both basal and induced transactivation [144].
ABCA1, ABCG1, ABCG5, and ABCG8: ATP-binding cassette transporters; AP1: transcription factor activator protein 1; AHR: aryl hydrocarbon receptor
(AHR); ARNT: aryl hydrocarbon receptor (AHR)/AHR nuclear translocator protein; ANG: angiotensin; AOx, acyl-CoA oxidase; ApoE: apolipoprotein E;
bHLH-PAS: basic helix–loop–helix–PAS; AR: androgen receptor; BAFs: Brm- or Brg-1-associated factors; BARE: bile acid response element; Brm: human
Brahma; CAR: constitutive androstane receptor; CBP: CREB-binding protein; C/EBPα: CCAAT/enhancer-binding protein α; CETP: cholesteryl ester transfer
protein; CREB: coactivator cAMP-response element-binding protein; CYP7A1: cholesterol-7-α-hydroxylase; DAX1: dosage-sensitive sex reversal adrenal
hypoplasia congenita critical region on the X chromosome: gene 1; DBD: DNA-binding domain; 6-ECDCA, 6-ethylchenodeoxycholic acid; EID1: E1A-
like inhibitor of diﬀerentiation 1; ER: estrogen receptor; ERRγ: estrogen receptor-related receptor-γ; FBP1: fructose-1,6-bisphosphatase; FXR: farnesoid
X receptor; G6Pase: glucose-6-phosphase; GR: glucocorticoid receptor; GPS2: G protein pathway suppressor 2; HD: enoyl-CoA hydratase/3-hydroxyacyl-
CoA dehydrogenase; HDACs: histone deacetylases; HDAC-1: histone deacetylase-1; HDAC-1: histone deacetylase-3; JunD: predominat Jun family protein;
HNF3/Foxa: hepatocyte nuclear factor-3; HNF4: hepatocyte nuclear factor-4; LPS: lipopolysaccharides; LXRα:l i v e rXr e c e p t o r α; LRH-1: liver receptor
homologue-1; miRNAs (miR): microRNAs; NcoR: nuclear receptor corepressor; NF-κB: nuclear factor-κB; Nur77: nuclear growth factor I-B; PEPCK:
phosphoenolpyruvate carboxykinase; PPRE: peroxisome proliferator-response elements; PXR: pregnane X receptors RAR: retinoid acid receptor; RNA Pol II:
RNA polymerase II; RXR: retinoid X receptor; SIRT1: sirtuin1; SREBP-1c: sterol regulatory element-binding protein-1c; TCDD, 2,3,7,8-tetrachlorodibenzo-
p-dioxin; TFIID: transcription initiation factor II D (TFIID); TFIIE: transcription factor II E; TGF-β: transforming growth factor-β; TLRs: Toll-like receptors;
TR: thyroid receptor; TRAF6: TNF-receptor-associated factor-6; XRE, xenobiotic response element; YY1: Ying Yang 1.
via the FXR pathway. In this respect, HNF1α (−/−)m i c e
displayed a defect in bile acid transport, increased bile
acid and liver cholesterol synthesis, and impaired HDL
metabolism [69].
A role for SHP in mediating the recruitment of mSin3A-
Swi/Snf to the CYP7A1 promoter, with chromatin remod-
eling and gene repression, has been described. In HepG2
cells, Kemper et al. [50] have shown that bile acid treatmentJournal of Lipids 9
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Figure 2:TheSHP-mediatedrepressionoftargettranscriptionfactorsoccursbyatleastthreedistincttranscriptionalrepressionmechanism:
(a) direct interference with the AF-2 coactivator domain of NRs (competition for coactivator binding, leading to the repression of NR-
mediated transcriptional activity); (b) recruitment of corepressors, resulting in active repression; (c) direct interaction with the surface of
NR or transcription factor, resulting in the blockade of DNA binding and the consequent inhibition of its transcriptional activity. See text
for details. The dotted arrows and (-) symbols indicate inhibition. CoA: coactivator; CoR: corepressor; NR: nuclear receptor; SHP: small
heterodimer factor; TF: transcription factor. Modiﬁed after [12, 15, 131].
resulted in SHP-mediated recruitment of transcriptional
coregulators mSin3A and Swi/Snf complex to the promoter,
chromatin remodeling, and gene repression (Table 3). This is
an additional mechanism involving transformation of nucle-
osome conformation for the repression by SHP of genes acti-
vatedbyvariousNRs.Inlinewithsuchresults,increasedsyn-
thesis and accumulation of BAs occurs in SHP (−/−)m i c e ,
due to the loss of SHP repression and consequent dere-
pression of the rate-limiting CYP7A1 and cholesterol 12α-
hydroxylase (CYP8B1) (the rate-determining enzyme of the
alternative but minor BA synthesis pathway) in the biosyn-
thetic pathway [70–72].
Mechanisms independent of the FXR/SHP/LRH pathway
might also exist, since BAs feeding to SHP (−/−)m i c e
reduced the levels of CYP7A1 mRNA to similar levels of
controlmice[70,71].SuchSHP-independentandalternative
pathwaysincludetheproteinkinaseC/JunN-terminalkinase
(PKC/JNK) pathway [73], the FXR/FGFR4 (FGF receptor
4) pathway [57, 74], the cytokine/JNK pathway [75], the
pregnane X receptor (PXR) mediated pathway [76], and the
JNK/c-Jun signaling pathway [77].
Another study demonstrated, in SHP (−/−)m i c eo n
a background of 129 strain, the protection against hyper-
cholesterolemia in three diﬀerent models: an atherogenic
diet,hypothyroidism,andSHP(−/−)miceintercrossedwith
LDLR (−/−) mice (to generate SHP/LDLR double (−/−)
mice in a mixed 129-C57BL/6 background). When fed an
atherogenic diet, the latter strain was almost completely
resistant to diet-mediated increases in triglyceride, very low-
density lipoprotein (VLDL) cholesterol, and low-density
lipoprotein (LDL) cholesterol but had an increase in high-
density lipoprotein (HDL) cholesterol as compared with
LDLR (−/−) mice. Such results point to the protection
against dyslipidemia following the inhibition of hepatic SHP
expression, although no antagonist ligands have yet been
identiﬁed for SHP [78]. We have recently examined biliary
lipid secretion and cholesterol gallstone formation in male
SHP (−/−) and (+/+) mice before and during the feeding
of a lithogenic diet for 56 days [79]. Deletion of the Shp
gene signiﬁcantly increased hepatic bile salt synthesis, and
doubledtheincreaseofbiliarybilesaltoutputsinSHP(−/−)
micethanin(+/+)mice.Theintestinalbileacidpoolsizewas
signiﬁcantly greater in SHP (−/−) mice than in (+/+) mice.
These increased BAs are eﬃcacious ligands of FXR and can
stimulate the expression of intestinal ﬁbroblast growth factor
15 (FGF15) in mice through the FXR signaling pathway,
which is consistent with the expanded bile acid pool size in
SHP (−/−) mice. At 14 days on the lithogenic diet, fasting
gallbladder volume was signiﬁcantly larger in SHP (+/+)
mice than in (−/−)m i c e[ 80].
Indeed, FGF15/19 (mouse and human orthologs, resp.)
is another FXR gene target in the intestine and appears to
contributetotheﬁnetuningofbileacidsynthesisintheliver.
Thus, a model for FXR-mediated repression of bile acid syn-
thesis should also take into account the bile acid-mediated
activation of intestinal FXR and FGF15 in the small intestine
(while the FXR-SHP pathway is activated in the liver).
According to the most plausible view, FGF15 acts as a
hormone to signal between intestine and liver. The secreted
FGF15 by the intestine circulates to the liver, likely through10 Journal of Lipids
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Figure 3: The potential molecular mechanisms of crosstalk between nuclear receptors LXR and FXR–SHP–LRH-1 regulatory cascade in the
liver and intestine. Bile acids act as ligands for FXR, which regulates transcription by binding as a heterodimer with RXRs. This step results
in increased SHP expression. SHP in turn inhibits LRH-1, preventing the activation of target genes that participate in bile acid and fatty acid
synthesis. In the absence of bile acids, LRH-1 acts together with LXR to stimulate bile acid synthesis [64, 65, 132]. The important pathways
in the intestine that contribute to modulation of bile acid synthesis are also depicted (see text for details). There is a bile-acid-mediated
activation of intestinal FXR and, as a result, the release of FGF15 in the small intestine. The secreted FGF15 by the intestine circulates to the
liver, likely through the portal circulation or lymph ﬂow [81] and induces the activation of FGFR4 in the liver. The FGF15/FGFR4 pathway
synergizes with SHP in vivo to repress CYP7A1 expression [57]. Bas: bile acids; FGF: ﬁbroblast growth factor; FGFR4: FGF receptor; FXR:
farnesoid X receptor; LRH-1: liver receptor homologue-1; LXR: liver X receptor; RXR: retinoid X receptors; SHP: short heterodimer partner.
Adapted from Ory [66] and Inagaki et al. [57].
the portal circulation or lymph ﬂow [81], and induces the
activation of FGFR4 in the liver. As shown in Figure 3, the
FGF15/FGFR4 pathway synergizes with SHP in vivo to re-
press CYP7A1 expression [57]. In humans, a similar mecha-
nism should involve the FGF19. Of note, activation of FXR
transcription in the intestine protected the liver from choles-
tasis in mice by inducing FGF15 expression and reducing
the hepatic pool of BA. This suggests a potential approach
to reverse cholestasis in patients [82]. Hepatic fatty acid
homeostasis is also regulated by SHP since regulating these
genesinvolvesinfattyaciduptake,synthesis,andexport[83–
87]. In a study exploring global gene expression proﬁling
combined with chromatin immunoprecipitation assays in
transgenic mice constitutively expressing SHP in the liver,
overexpression of SHP in the liver was associated with the
depletion of the hepatic bile acid pool and a concomitant
accumulationoftriglyceridesintheliver[84].Bycontrast,fat
accumulation induced by a high-cholesterol or high-fat diet
is prevented by the deletion of SHP [88, 89]. The pleiotropic
role of SHP can also be found in the case of nonalcoholic
liver steatosis since OB/SHP double (−/−)m i c e( am o d e l
of severe obesity and insulin resistance) became resistant to
liver steatosis and showed improved insulin sensitivity [86].
Another interesting role for SHP emerged after it was
found that BAs negatively regulate the human angiotensino-
gen (ANG) gene. ANG is the precursor of vasoactive octa-
peptideangiotensinII,andBAsactthroughtheSHPpathway
by preventing hepatocyte nuclear factor-4 (HNF4) from
binding to the human ANG promoter [90].
3.FatMass, Adipocytes,andObesity
SHP appears to play a central role in obesity. Human obesity
is considered a polygenic disorder characterized by partly
known abnormal molecular mechanisms resulting in in-
creased fat mass, with an imbalance between the energy
acquired from nutrients that dissipated as heat (i.e., thermo-
genesis). In this respect, weight stability requires a balance
between calories consumed and calories expended [91]. In
adipose tissue depots, two main types of adipocytes exist,
that is, brown adipocytes and white adipocytes. In several
animal species, some adipose tissue sites mainly include
brown adipocytes (BATs) and the other contains mainly
white adipocytes (WATs). BAT dissipates chemical energy to
produceheateitherasadefenseagainstcold[92]orasenergy
expendituretocompensatefoodintake[93,94].TheunusualJournal of Lipids 11
function of BAT might be better understood by considering
that they share a common origin with myocytes [95, 96], and
BAT was indeed considered something in between muscle
and adipose tissue [95]. BAT is deemed as the major site for
sympathetic (adrenergic) mediated adaptive thermogenesis;
this pathway involves the uncoupling protein-1 (UCP1).
WAT is mainly implicated in the regulation of lipid storage
and catabolism but also in the synthesis and secretion of
adipokines [97–100]. While the percentage of young men
with BAT is high, the activity of BAT is reduced in men who
are overweight or obese [101]. Thermogenesis unequivocally
exists in both humans and animals, and BAT is the major site
of thermogenesis which can be increased by environmental
factors (i.e., adaptive thermogenesis). In both human and
animal species, dietary composition, chronic cold exposure,
and exercise may increase thermogenesis [102]. As far as
adipose tissue biology is concerned, SHP seems to play a
distinct regulatory function in WAT, as compared with BAT.
A number of experiments have focused on animal models of
obesityandsubtlemolecularchanges.SHP-deﬁcientmiceare
protected against high-fat-diet-induced obesity [89].
Peroxisome proliferator-activated receptor (PPAR) γ co-
activator-1 (PGC-1) family members are multifunctional
transcriptional coregulators. PGC-1 acts as a molecular
switch in several metabolic pathways. In particular, PGC-
1α and PGC-1β regulate mitochondrial biogenesis, adaptive
thermogenesis, fatty acid and glucose metabolism, ﬁber-type
switching in skeletal muscle, peripheral circadian clock, and
development of the heart [103]. In particular, SHP functions
as a negative regulator of energy production in BAT [89]
because SHP is a negative regulator of PGC-1α expression in
BAT. In turn, PCG-1α is a coactivator of uncoupling protein
1 (UCP1) which plays a major role in energy dissipation
as heat in multilocular BAT of diﬀerent animal species and
humans [104–106]. Fat-speciﬁc (BAT) SHP-overexpressed
transgenic mice had increased body weight and adiposity.
Energy metabolism, however, was increased, and BAT cold
exposure function was enhanced with activation of ther-
mogenic genes and mitochondrial biogenesis (enhanced β1-
AR gene expression and PGC1α). Compared with wild-type
mice on a high-fat diet, SHP overexpression was associated
with enhanced diet-induced obesity phenotype with weight
gain, increased adiposity, and severe glucose intolerance. An
additional feature of SHP transgenic mice was a decreased
diet-induced adaptive thermogenesis, increased intake of
food, and decreased physical activity [107]. This leads to
the conclusion that, although expressed at low levels in
fat, activation of SHP in adipocytes has a strong eﬀect on
weight gain and diet-induced obesity [107]. Moreover, if
mechanisms linked to energy metabolism and the devel-
opment of obesity are considered, SHP has distinct roles
in WAT and BAT. As previously mentioned, while SHP
deletion in obese leptin-deﬁcient mice (ob/ob)p r e v e n t e d
the development of nonalcoholic fatty liver and improved
peripheral insulin sensitivity [86], SHP deletion did not
overcome the severe obesity caused by leptin deﬁciency. A
signiﬁcant protective eﬀect from obesity by SHP deﬁciency
waslikelyassociatedwiththelowbasallevelofSHPexpressed
in fat. Adipogenesis appears to be inﬂuenced by SHP: when
SHP was overexpressed in 3T3-L1 preadipocytes, cell diﬀer-
entiation was inhibited, as well as the accumulation of neu-
tral lipids within the cells. Thus, SHP may act as a molecular
switch governing adipogenesis. In particular, SHP appears
to be a potent adipogenic suppressor, and preadipocytes are
kept in an undiﬀerentiated state through the inhibition of
the adipogenic transcription factors and stimulators [108].
Furtherstudies willaddress whetherthe lossof SHP function
results in inhibition of lipid accumulation in adipocytes,
similar to what is observed in hepatocytes. In a future clinical
setting, treatment of obesity might also include drugs able to
mimic or stimulate the eﬀects of SHP. Mutations in the Shp
gene have also been reported in patients with lipodystrophy
carrying four diﬀerent polymorphisms [109].
SHP mutations may not be considered a common cause
of severe obesity. A number of important clinical studies
have examined this issue (Table 4); however, Hung et al.
[110] in UK examined the relationships between genetic
variation in SHP and weight at birth, adiposity, and insulin
levels in three diﬀerent populations (the Genetics of Obesity
Study) GOOS, the Avon Longitudinal Study of Parents and
Children (ALSPAC), and the Ely studies). In the 329 cases of
severe early-onset obesity (GOOS study), two novel and rare
missense mutations (R34G and R36G) were identiﬁed which
might in part contribute to obesity in the probands. Further-
more, two common polymorphisms, namely, G171A (12%
of subjects with higher birth weight) and −195CTGAdel
(16% of subjects with lower birth weight) were found. In
the ALSPAC cohort of 1,079 children, the G171A variant
was associated with increased body mass index and waist
circumference together with higher insulin secretion 30
minutes after glucose load. Thus, whereas mutations in the
Shp gene cannot be seen as a common cause of severe human
obesity, genetic variation in the Shp gene locus may inﬂuence
b i r t hw e i g h ta n dh a v ee ﬀects on body size. The eﬀect might
ultimatelyinvolveinsulinsecretionbythenegativeregulation
between SHP and the hepatocyte nuclear factor-4α (HFN-
4α), a transcription factor involved in diﬀerentiation and
function of pancreatic β-cells [110].
ApossibilityisthatdecreasedSHP expressionorfunction
results in increased HFN-4α activity with a cascade of events,
includingfetalhyperinsulinemia,andincreasedbirthweight.
Atalaterstage,sustainedhyperinsulinemiamightberespon-
sible of insulin resistance and obesity of the adult [110].
Mutations in the Shp gene were also associated with
inﬂuence on birth weight, mild obesity, and insulin levels in
the study by Nishigori et al. on 274 Japanese subjects [111].
Mutations in several genes encoding transcription factors
of the hepatocyte nuclear factor (HNF) cascade are associ-
ated with maturity-onset diabetes of the young (MODY).
MODY is a monogenic form of early-onset diabetes mellitus
(defective insulin secretion with normal body weight), and
SHP is deemed as a plausible candidate MODY gene; this is
because SHP is able to inhibit the transcriptional activity of
the hepatocyte nuclear factor-4α (HFN-4α), a key member
of the MODY regulatory network. Thus, further studies have
looked for segregation of SHP m u t a t i o n sw i t hM O D Yi n
a cohort of Japanese patients with early-onset diabetes. In
this context, variants in SHP appeared to cosegregate with12 Journal of Lipids
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increased body mass index in families, thus contributing
to obesity among Japanese subjects. Also, increased risk
of morbidity was observed in another study from Japan,
examining patients with type 2 diabetes and SHP mutations
[112].
Major diﬀerences, however, might exist in the prevalence
and function of SHP variants in diﬀerent populations. Of
note, the results from other Caucasian cohorts did not
conﬁrm the association between SHP mutation and obesity
[113, 114]. Echwald et al. conducted an elegant study on the
prevalence of SHP variants by single-strand conformational
polymorphismandheteroduplexanalysisamong750Danish
obese men with early-onset obesity [114]. As control, a
cohort of 795 nonobese control subjects was genotyped
usingPCR-RFLP.Functionalanalysesoftheidentiﬁedcoding
region variants were performed in both MIN6-m9 and
HepG2 cell lines. Five novel variants were identiﬁed (includ-
ing 3 missense variants (c.100C>G [p.R34G], c.278G>A
[p.G93D], and c.415C>A [p.P139H]) and 2 silent variants
(c.65C>T [p.Y22Y] and c.339G>A [p.P113P])). The previ-
ously reported [111] c.512G>C [p.G171A] common poly-
morphism was identiﬁed; however, the prevalence of func-
tional SHP variants associated with obesity was considerably
lower among Danish subjects (1 out of 750 obese, none
of control subjects), compared to the prevalence observed
in Japan by Nishigori et al. [111]. Mitchell at al. [113]
investigated SHP variants in 1927 UK subjects according
to type 2 diabetes, obesity, and birth weight. Although
reporting a raised body mass index among homozygous
carriers of the 171A variant (<1%), this polymorphism
was unlikely to be associated with all three conditions in
Caucasians. Taken together, the above-mentioned studies
suggest that the 171A variant might contribute only to
subsets of polygenic obesity.
4. Other Functions of SHP
The existence of multiple interactions of SHP with NRs,
transcription factors and transcriptional cofactors (Tables 2
and 3) points to the pleiotropic and central role of SHP in
the body.
SHP has been hypothesized to act in glucose home-
ostasis via complex pathways involving the inhibition of
glucocorticoid receptors (GR) in mammalian cells and the
inhibition of PGC-1 gene, a coactivator of NRs important
for gluconeogenic gene expression and the PGC-1-regulated
phospho(enol)pyruvate carboxykinase (PEPCK) promoter.
Such steps underscore a physiologically relevant role for SHP
in modulating hepatic glucocorticoid action [22]. Following
the bile acid-induced induction, SHP inhibited a number
of other pathways, including the HNF4α-mediated trans-
activation of the PEPCK and fructose biphosphate (FBP)
promoters, as well as the transactivation of the glucose-6-
phosphatase (G6Pase) promoter mediated by Foxo1 [115].
The interaction between SHP inhibitory function and the
3i s o f o r m s( α, β,a n dγ) of the hepatocyte nuclear factor-3
(HNF4) points to the regulatory role of SHP on gluconeo-
genesis [51]. A role for SHP in insulin secretion pathway has
also been reported. Mutations in hepatocyte nuclear factor
1α (HNF-1α) is associated with maturity-onset diabetes of
the young type 3. This condition depends on impaired
insulin secretory response in pancreatic beta cells.
Indeed, loss of HNF-1α function in HNF-1α (−/−)m i c e
resulted in altered expression of genes involved in glucose-
stimulated insulin secretion, but also insulin synthesis, and
beta-cell diﬀerentiation. Pancreatic islets of HNF-1α (−/−)
mice showed a distinctive reduction of SHP expression and
a downregulation of the HNF4α gene expression. Since SHP
appears to repress its own transcriptional activation follow-
ing heterodimerization with HNF4α, a feedback autoregula-
tory loop between SHP and HNF4α has been hypothesized
[116]. Also, SHP likely functions as a negative regula-
tor of pancreatic islet insulin secretion. SHP (−/−)m i c e
were characterized by hypoinsulinemia, increased glucose-
dependent response of islets, increased peripheral insulin
sensitivity, and increased glycogen stores [117]. The role
played by SHP in the regulation of hepatic gluconeogenesis
has also emerged in a number of additional experiments.
For example, the liver of SHP (−/−) mice showed increased
glycogen stores [117], while hepatic Shp gene expression
(induced by the antidiabetic biguanide drug metformin) was
associatedwithinhibitionofhepaticgluconeogenesis.Induc-
tion of SHP was achieved via AMP-activated protein kinase
(AMPK) and associated with downregulation of essential
gluconeogenic enzyme genes, that is, phosphoenolpyruvate
carboxykinase (PEPCK), glucose-6-phosphatase (G6Pase)
[118], and fructose-1,6-bisphosphatase (FBP1) [119].
PGC-1 gene is a coactivator of NRs, and this step is
relevant for gluconeogenic gene expression. Yamagata et al.
[119] showed that bile acid (chenodeoxycholic acid) was
able to induce the downregulation of PGC-1 gene, and this
mechanism involved forkhead transcription factors (Foxo1,
Foxo3a, Foxo4) via a SHP-dependent manner.
Drug metabolism and detoxiﬁcation might be regulated
by SHP. This is also the case for excess BAs: the pregnane X
receptor (PXR) induces CYP3A and inhibits CYP7α,b o t h
involved in biochemical pathways leading to the conversion
o fc h o l e s t e r o li n t op r i m a r yB A s ,w h e r e a sC Y P 3 Ai sa l s o
involved in the detoxiﬁcation of toxic secondary bile acid
derivatives. SHP acts as a potent repressor of PXR transac-
tivation, and this ﬁnding suggests that PXR can act on both
bile acid synthesis and elimination detoxiﬁcation [1]. Addi-
tional mechanisms involved in the SHP-dependent control
of pathways of drug metabolism have been identiﬁed. The
expression of genes involved with the metabolism of xeno-
biotics might be regulated by SHP in the spleen acting
on (aryl hydrocarbon receptor (AHR)/AHR nuclear translo-
cator (ARNT)) AHR/ARNT heterodimers which, in turn,
bind to xenobiotic response elements (XREs) at the level
of speciﬁc DNA sequences [41]. A number of genes involved
in hormone and drug metabolism would be expressed (i.e.,
UGT16, ALDH3, CYP1A1, CYP1A2, CYP1B1, etc.). SHP
also appears to downregulate the constitutive-androstane-
receptor- (CAR-) mediated CYP2B1 gene expression, in-
duced by phenobarbital to form the CAR/RXR heterodimer
which, in turn, binds to 2 DR-4 sites to form the phenobar-
bital responsive unit in the CYP2B gene [120]( Table 3). One
roleofSHPinsteroidogenesishasbeenidentiﬁedinthetestesJournal of Lipids 15
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Figure 4: Schematic diagram of the function and gene regulation of SHP. Diﬀerent conditions will lead to activation of nuclear receptors
and/or transcription factors able to regulate Shp gene expression in the nucleus and protein synthesis in the cytoplasm. The protein acts as a
transcriptional corepressor of a number of other nuclear receptors and transcription factors involved in a wide series of regulatory pathways.
The potential role of a feedback mechanism and of ligand(s) is hypothesized.
with inﬂuence on testosterone synthesis and germ cell diﬀer-
entiation [121] and in the intestine for glucocorticoid syn-
thesis [122].
Ar o l ef o rS H Pi nc e l lp r o l i f e r a t i o na n da p o p t o s i s
signalingisemerging.Dependingonthecelltype,SHPseems
to have both inhibitory and stimulatory eﬀects on apoptosis.
However, the manipulation of SHP through the synthetic
ligands adamantyl-substituted retinoid-related (ARR) com-
pounds 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphtha-
le-necarboxylic acid (CD437/AHPN) and 4-[3-(1-adaman-
tyl)-4-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC)
induces apoptosis of a number of malignant cells (i.e., leu-
kemia and breast carcinoma) both in vitro and in vivo [123,
124]. The complex mechanism implies binding of ARR and
3-Cl-AHPC to SHP with formation of a corepressor complex
containing Sin3A and nuclear receptor corepressor (N-CoR)
which activate local control of mitochondrial function and
apoptosis, with a limiting function on tumorigenesis [17,
123]( Table 3). SHP appears to be also involved in DNA
methylation and acting as a tumor suppressor, at least in the
human and mouse livers [125–127]. Whether manipulation
of SHP will be helpful in the treatment of hepatic and other
gastrointestinal cancers is still a matter of research. The
recent ﬁnding that SHP negatively regulates TLR signaling to
NF-κB has raised the interest for the role of SHP in mecha-
nismsgoverninginnateimmunity.SHPappearstonegatively
regulate the expression of genes encoding inﬂammatory
molecules. Of note, direct binding of NF-κBs e e m st oo c c u r
in resting cells, while binding of SHP to TRAF6 occurs in
LPS-stimulated cells [128, 129].
5. Conclusions and Perspectives
A remarkable number of metabolic functions in the body
appear to be regulated by the orphan unique NR, small
heterodimer partner SHP, which targets a complex set of
genes in multiple pathways as a transcriptional corepressor
(Figure 4). Pathways include fatty acid metabolism, glu-
cose homeostasis, and drug-hormone detoxiﬁcation. When
looking at complex mechanisms leading to some important
lipidopathies, that is, obesity and liver steatosis, enlightening
data about the regulatory function of SHP are provided
by studies using Shp-deleted and Shp-overexpressed animal
models. Most likely, a condition of Shp deﬁciency might16 Journal of Lipids
counteract lipid accumulation and improve plasma lipopro-
tein proﬁles. Further studies are urgently needed to conﬁrm
that such an important metabolic regulatory mechanism
of SHP is true and has high translational value. To date,
however, no synthetic antagonists or agonists for SHP are
available, and one should keep in mind that rather divergent
and somewhat elusive data have been observed regarding the
loss of SHP function in humans and rodents. Thus, careful
examination of subtle SHP intrinsic functions is essential
to dissect potential modulatory pathways of SHP for a
variety of metabolic abnormalities but also in tumorigenesis.
Moreover, identifying speciﬁc endogenous ligands and syn-
thetic agonists of SHP will pave the way to for therapeutic
intervention. The eﬀect of synthetic ligands on SHP mod-
ulation in hepatocytes and adipocytes, for example, might
represent therapeutic tools for the treatment of constituents
of the metabolic syndrome, namely, hypercholesterolemia,
overweight obesity, and liver steatosis.
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